CLINICAL PHARMACOLOGY OF PERSONALIZED DRUG THERAPY: CURRENT APPROACHES AND FUTURE PERSPECTIVES
Keywords:
personalized medicine; clinical pharmacology; pharmacogenomics; therapeutic drug monitoring; model-informed precision dosing; biomarkers; clinical decision support.Abstract
Personalized drug therapy seeks to optimize medication selection and dosing by integrating patient-specific determinants of pharmacokinetics, pharmacodynamics, efficacy and toxicity. This structured literature-based review summarizes current clinical pharmacology approaches that support individualized treatment and evaluates their practical convergence. A targeted review of international peer-reviewed literature and major pharmacogenetic guidance was performed, emphasizing pharmacogenomics, therapeutic drug monitoring (TDM), model-informed precision dosing (MIPD), organ-function-based dose adjustment, biomarkers, drug-interaction assessment and clinical decision support. Evidence synthesis shows that clinically actionable personalization is strongest when a measurable source of variability is linked to a specific prescribing action. Pharmacogenetic guidance is established for several high-impact gene-drug pairs, while TDM and MIPD are particularly valuable for medicines with narrow therapeutic indices or marked exposure variability. Multimodal approaches that combine genotype, phenotype, laboratory data and longitudinal response provide a more robust basis for dose adaptation than any single data stream. Important barriers include unequal access to testing, population diversity, data interoperability, model validation and clinician workflow. The future of personalized pharmacotherapy will likely depend on validated decision-support systems that integrate pharmacogenomics, real-time monitoring and explainable predictive models while retaining clinician oversight.
References
1.Roden, D. M., McLeod, H. L., Relling, M. V., Williams, M. S., Mensah, G. A., Peterson, J. F., & Van Driest, S. L. (2019). Pharmacogenomics. The Lancet, 394(10197), 521-532. https://doi.org/10.1016/S0140-6736(19)31276-0
2.Verstegen, R. H. J., & Ito, S. (2019). The future of precision medicine. Clinical Pharmacology & Therapeutics, 106(5), 903-906. https://doi.org/10.1002/cpt.1622
3.Relling, M. V., Klein, T. E., Gammal, R. S., Whirl-Carrillo, M., Hoffman, J. M., & Caudle, K. E. (2020). The Clinical Pharmacogenetics Implementation Consortium: 10 years later. Clinical Pharmacology & Therapeutics, 107(1), 171-175. https://doi.org/10.1002/cpt.1651
4.Denny, J. C., & Collins, F. S. (2021). Precision medicine in 2030-seven ways to transform healthcare. Cell, 184(6), 1415-1419. https://doi.org/10.1016/j.cell.2021.01.015
5.Lee, C. R., Luzum, J. A., Sangkuhl, K., Gammal, R. S., Sabatine, M. S., Stein, C. M., et al. (2022). Clinical Pharmacogenetics Implementation Consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clinical Pharmacology & Therapeutics, 112(5), 959-967. https://doi.org/10.1002/cpt.2526
6.Johnson, J. A., Caudle, K. E., Gong, L., Whirl-Carrillo, M., Stein, C. M., Scott, S. A., et al. (2017). Clinical Pharmacogenetics Implementation Consortium guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clinical Pharmacology & Therapeutics, 102(3), 397-404. https://doi.org/10.1002/cpt.668
7.Swen, J. J., van der Wouden, C. H., Manson, L. E. N., Abdullah-Koolmees, H., Blagec, K., Blagus, T., et al. (2023). A 12-gene pharmacogenetic panel to prevent adverse drug reactions: An open-label, multicentre, controlled, cluster-randomised crossover implementation study. The Lancet, 401(10374), 347-356. https://doi.org/10.1016/S0140-6736(22)01841-4
8.Pratt, V. M., Cavallari, L. H., Fulmer, M. L., Gaedigk, A., Hachad, H., Ji, Y., et al. (2024). DPYD genotyping recommendations: A joint consensus recommendation. The Journal of Molecular Diagnostics, 26(10), 851-863. https://doi.org/10.1016/j.jmoldx.2024.05.015
9.Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadee, W., et al. (2015). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP3A5 genotype and tacrolimus dosing. Clinical Pharmacology & Therapeutics, 98(1), 19-24. https://doi.org/10.1002/cpt.113
10.Maillard, M., Schwab, M., Whirl-Carrillo, M., Moyer, A. M., Suarez-Kurtz, G., Pui, C.-H., et al. (2026). Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2025 update. Clinical Pharmacology & Therapeutics, 119(4), 916-927. https://doi.org/10.1002/cpt.70209
11.Momper, J. D., & Wagner, J. A. (2014). Therapeutic drug monitoring as a component of personalized medicine: Applications in pediatric drug development. Clinical Pharmacology & Therapeutics, 95(2), 138-140. https://doi.org/10.1038/clpt.2013.227
12.Minichmayr, I. K., Dreesen, E., Centanni, M., Wang, Z., Hoffert, Y., Friberg, L. E., & Wicha, S. G. (2024). Model-informed precision dosing: State of the art and future perspectives. Advanced Drug Delivery Reviews, 215, 115421. https://doi.org/10.1016/j.addr.2024.115421
13.Poweleit, E. A., Vinks, A. A., & Mizuno, T. (2023). Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. Therapeutic Drug Monitoring, 45(2), 143-150. https://doi.org/10.1097/FTD.0000000000001078
14.Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., et al. (2023). CPIC guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clinical Pharmacology & Therapeutics, 114(1), 51-68. https://doi.org/10.1002/cpt.2903
15.Wake, D. T., Smith, D. M., Kazi, S., & Dunnenberger, H. M. (2022). Pharmacogenomic clinical decision support: A review, how-to guide, and future vision. Clinical Pharmacology & Therapeutics, 112(1), 44-57. https://doi.org/10.1002/cpt.2387
